Hematopoietic Stem Cell Transplantation for Multiple Sclerosis: Collaboration of the CIBMTR and EBMT to Facilitate International Clinical Studies  by Pasquini, Marcelo C. et al.
WORKSHOP SUMMARYFrom the
Resea
sin; 2
Natio
Institu
Neuro
4Bloo
Hosp
Swedi
ment
7Depa
Ontar
Unive
of Ne
Geno
Clinic
Neuro
Germ
Medic
Hutch
ington
State
1076Hematopoietic Stem Cell Transplantation for Multiple
Sclerosis: Collaboration of the CIBMTR and EBMT to
Facilitate International Clinical Studies
Marcelo C. Pasquini,1 Linda M. Griffith,2 Douglas L. Arnold,3 Harold L. Atkins,4
James D. Bowen,5 Jacqueline T. Chen,3,6 Mark S. Freedman,7 George H. Kraft,8
Gian Luigi Mancardi,9 Roland Martin,10 Paolo A. Muraro,11 Richard A. Nash,12
Michael K. Racke,13 Jan Storek,14 Riccardo Saccardi15Clinical investigation of autologous hematopoietic stem cell transplantation (HSCT) as therapy for multiple
sclerosis (MS) has been ongoing for over a decade.While several phase II studies have been finalized or are in
progress, no definitive prospective randomized studies comparing HSCT versus alternative therapies for MS
have been completed. In this conference report of North American and European experts who are involved
in the care of MS patients, including neurologists and HSCT physicians, and representatives of the Center for
International Blood and Marrow Transplant Research (CIBMTR) and European Group for Blood and Marrow
Transplantation (EBMT), we (1) critically review progress to date in HSCT for MS; (2) describe current reg-
istry based projects including long-term follow-up studies in HSCT for MS and harmonization of the MS dis-
ease-specific research forms that will be used in future by both databases; (3) discuss challenges in study
design for a prospective randomized clinical trial of HSCT versus alternative therapy for MS such as feasibility,
and the importance of multidisciplinary clinical teams, need for a large sample size and duration of observa-
tion required for outcomes assessment; and (4) address future directions in HSCT therapy for MS. To un-
dertake a definitive multicenter clinical trial in autologous HSCT for MS, it will be important to begin well in
advance to assemble the team, evaluate proposals for study design, and consider options for the infrastruc-
ture and logistical support that will be needed. International collaboration, including partnership with the
CIBMTR and EBMT, may be desirable and may in fact be critical for successful completion of a definitive com-
parative study.
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Figure 1. Possible outcomes of autologous HSCT for MS. The objec-
tive of autologous HSCT for MS is to reduce inflammation and progres-
sion of the disease for a prolonged period. Early MS, which has
characteristic lesions demonstrating active inflammation, has a chronic
relapsing remitting course and is followed by progressive disease in later
years. There is growing evidence that the clinical effects of autologous
HSCTare not limited to transient immune suppression (top), but could
be related to a ‘‘resetting’’ of the immune system [3]. However, several
years of long-term follow-up of patients undergoing HSCT for MS is
needed to determine durability of remission from clinical disease
activity. Immunologic mechanistic studies using patient samples and
MRI studies to assess demyelination and remyelination are also needed
to elucidate the mechanisms of HSCT’s effects on MS.
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For more than a decade, clinical investigation of
autologous hematopoietic stem cell transplantation
(HSCT) as therapy for multiple sclerosis (MS) has
been ongoing. Several phase II studies have been
completed or are in progress; however, no definitive
prospective randomized studies comparing HSCT
versus alternative therapies for MS have been com-
pleted. The objectives of this 1.5-day workshop
were to review ongoing studies of the Center for In-
ternational Blood and Marrow Transplant Research
(CIBMTR) and European Group for Blood and
Marrow Transplantation (EBMT) in MS, including
harmonization of the MS disease-specific report
forms, and to explore mechanisms through which
the databases might serve as a resource to facilitate
collaboration on the scale needed for pivotal studies.
We sought to critically review progress to date in
HSCT for MS, identify challenges to the advance-
ment of this therapeutic modality, and discuss
opportunities for future collaborative clinical trials.
Meeting participants included HSCT physicians,
neurologists, and imaging experts with particular
interest in MS clinical research and immunologic
mechanisms from North America and Europe.BACKGROUNDAND CURRENT CLINICAL
TRIALS
Thepurposeofhigh-dose immunosuppressive ther-
apy (HDIT) with autologous HSCT is to stop the in-
flammation associated with MS [1,2] and thereby
preserve neurologic function. The autologous graft
serves to rescue hematopoietic activity after HDIT or,
in the case of less immunosuppressive therapy, to
reduce the time to recovery of blood counts.
Generation of a new and diverse T cell immune
response may be one mechanism of action to explain
the fact that the remission of inflammatory disease
activity extends much longer than the duration of
immune suppression (Figure 1) [3]. Currently, MS is
the most common autoimmune disease indication for
autologous HSCT [4-6]. Following the initial
promising clinical experience [7], more than 350 con-
secutive cases have been reported by the EBMT over
the last decade [8,9]. Most patients who underwent
autologous HSCT for MS in the early studies had
secondary progressive MS, and relatively fewer had
relapsing remitting disease, with a Kurtzke Extended
Disability Severity Score (EDSS) [10] of 3.0-9.5 at the
time of transplantation [4]. Improvements in supportive
care and patient selection have contributed to improved
outcomes, with a significant reduction in treatment-
related mortality to 1.3% seen during 2001-2007 [4,6].
Recent studies have enrolled patients with earlierdisease and are supportive of a role for intense
immunosuppression with autologous HSCT as
treatment for rapidly evolving MS unresponsive to
conventional therapies [11-14]. Clinical studies
performed to date have recently been comprehensively
reviewed [4], and the retrospective report of the
EBMT database in MS has been updated [8,9].
At least one prospective randomized study and
other single-arm phase II studies of autologous
HSCT for MS are currently active in the United
States, Canada, and Europe (Table 1). Because it is
now generally accepted that administering HDIT
relatively early in the course of the disease to reduce
inflammation before irreversible neuronal damage
occurs is important, these studies target MS patients
with active disease and worsening disability as evi-
denced clinically by relapse, change in EDSS, and, or
inflammatory activity seen on magnetic resonance im-
aging (MRI), and who have failed at least one approved
first-line immunomodulatory MS therapy for enroll-
ment. Three of the studies either completed or closed
enrollment during 2009, and follow-up of several years
will be needed to evaluate outcomes, which will in turn
be important for designing the next clinical trial(s).REGISTRY STUDIES IN HSCT FOR MS
Both the CIBMTR and the EBMT collect infor-
mation about patients with MS who have undergone
Table 1. Phase II Studies in Autologous HCT for MS
Phase II Single-Arm Phase II Randomized
HALT MS ITN033AI MS BMT Canada ASTIMS EBMT Northwestern University
Transplantation arm
Mobilization GCSF + prednisone Cy + GCSF Cy + GCSF Cy + GCSF
Graft CD34 selected CD34 selected Unmanipulated Unmanipulated
Conditioning BEAM + ATG Busulfan + Cy BEAM + ATG Cy + ATG
Alternative arm
NA NA Mitoxantrone FDA-approved standard of care
Inclusion/exclusion
Target MS population Relapsing remitting or progressive
relapsing MS
Active MS with relapses or progression Relapsing remitting or progressive relapsing
or secondary progressive MS
Inflammatory MS failing interferon therapy
Age 18-60 18-50 18-50 18-55
EDSS 3.0-5.5 3.0-6.0 3.5-6.5 2.0-6.0
MS criteria Duration <15 years from
diagnosis; T2 abnormalities
on brain MRI consistent with MS; $ 2
relapses in <18 months; worsening
of EDSS; failure of standard drug therapy
MRI findings meet criteria of MS; evidence
of current disease activity including
worsening of EDSS in last 18 months
or 2 relapses in last year or 3 relapses
in last 3 years; failed at least one
immunosuppressive drug
Relapsing remitting MS with at least 2
relapses per year and enhancing lesions
on MRI; relapsing progressive MS with
worsening EDSS during last year and
enhancing lesions on MRI; secondary
progressive MS with worsening EDSS
during last year and enhancing lesions
on MRI unless rapid deterioration
Inflammatory disease, based on both
clinical and MRI activity, after$ 6 months
of interferon or copaxone therapy
Study design
Primary outcome Progression-free survival at 5 years Progression-free survival at 3 years New T2 lesions per year Progression-free survival at 5 years
Primary outcome measure EDSS and/or clinical relapse and/or new MRI
abnormalities consistent with MS
EDSS MRI imaging (EDSS is a secondary
outcome measure)
EDSS
Projected accrual 25 24 30 (21 accrued) 110
Date of activation July 2006; enrollment complete
September 2009
August 2001; enrollment complete July 2009 January 2005; closed November 2009
because of lack of accrual
January 2006; number enrolled not available
References ClinicalTrials.gov
NCT00288626; http://www.halt-ms.org
Atkins A, Freedman M (2009) [39];
Chen JT, et al. (2006) [40]
http://www.astims.org; Mancardi and
Saccardi (2008) [4]
ClinicalTrials.gov
NCT00273364
G-CSF indicates granulocyte colony-stimulating factor; Cy, cyclophosphamide; ATG, antithymocyte globulin; EDSS, Extended Disability Severity score; MS, multiple sclerosis.
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Table 2. MS Forms Harmonization by CIBMTR and EBMT
Assessment timeline
MS diagnosis Dates of onset of first symptoms and diagnosis of MS, family history of the disease, and imaging or laboratory evidence
of MS are recorded. Previous MS specific treatments, not including symptomatic treatment during relapses, are
documented.
Pre-HSCT MS disease course Disease manifestations within the 2-year interval immediately preceding HSCT are documented, including the number
of MS relapses, extent of MRI abnormalities, and disease course. The EDSS is also collected for 1 and 2 years before
presentation at the transplantation center, if available.
Note: If EDSS has not been determined during the 1-2 year pretransplantation interval, reconstruction may be attempted
by a study neurologist provided that there is an objective detailed chart. Some centers have formalized this process.
Baseline: MS assessment
immediately preceding HSCT
For autologous procedures, EDSS assessment andMRI findings are obtained within 2 weeks before administration of stem
cell mobilization agents (baseline scan) and again immediately before administration of the conditioning regimen.
Obtaining information about the mobilization as well as the postmobilization clinical assessment and MRI findings
will allow evaluation of any effect of the mobilization procedure on neurologic status. For allogeneic procedures,
EDSS is assessed and MRI findings are obtained within 2 weeks before administration of the conditioning
regimen (baseline scan).
Post-HSCT follow-up of MS
disease course
Follow-up is obtained at 6 months and 1 year posttransplantation, and yearly thereafter. Clinical relapses, including date
of each relapse, determined after HSCT, are documented. EDSS assessment of disease severity and imaging studies of
neurologic burden of disease are included. If necessary, any MS-specific treatments are recorded.
Challenges in forms design and completion
Forms design The clinical features and natural history of MS present certain challenges in designing of disease-specific registry forms.
For example, disease activity in MS may manifest as clinical relapse or exacerbation (flare), findings revealed by
neurologic imaging, and/or incremental worsening of the clinical scale are used to assess severity of disease.
Forms completion We recommend here aminimum data set for patients who receiveHSCT forMS. For patients with MSwho are enrolled in
treatment clinical trials of any type, most of the assessments will have been performed as a part of those studies. For
patients not enrolled in a clinical study, these suggestions may serve as guidance. To complete the neurology forms will
require collaboration with a neurologist, preferably the treating neurologist. To improve accuracy, completion of forms
in reasonable proximity to the events by staff familiar with MS is preferred. In addition, completion of MS-specific
quality-of-life assessments is desirable.
MRI MRI findings consistent with MS activity include new gadolinium-enhancing and/or new T2 lesions, as compared to
a baseline scan obtained before transplant. If available, MRI at 8 weeks post-HSCTalso may be used as a reference scan
comparator for later MRI studies.
MS indicates multiple sclerosis; HCT, hematopoietic stem cell transplantation; EDSS, Extended Disability Severity score.
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ment ofHealth andHumanServicesmandate to collect
information about all patients who undergo either
related or unrelated allogeneic HSCT for any indica-
tion; reporting of autologous HSCT is voluntary.
Most European centers report both allogeneic and
autologous HSCTs to the EBMT, although the
requirement to report allogeneic HSCT depends on
the country, and reporting of autologousHSCT is vol-
untary. As a part of this workshop, representatives of
the Autoimmune Diseases Working Committee of
the CIBMTR and the Autoimmune DiseasesWorking
Party of theEBMTmet to revise and harmonize the re-
search forms in HSCT for MS, which will be used in
the future by both registries (Table 2 and Figure 2).
To complete the registry forms at the patient care sites,
close partnerships between the transplantation and
neurology services are needed. Two registry-based
studies of HSCT for MS were discussed.Autologous HSCT in MS: Long-Term Follow-Up
To assess long-term follow-up of patients who
underwent autologous HSCT for MS, CIBMTR and
EBMT have approved a collaborative cross-sectional,
retrospective study of patients who underwent HSCT
between 5 and 12 years earlier. Up to 250 patients
from the combined registries might be eligible for fur-
ther study. We will obtain information about disease
status at baseline and the transplantation regimen usedfor each patient. Progression-free survival will be the
primary outcome. Secondary outcomesunder consider-
ation include interval changes in MS-specific imaging
(evolution ofMRIMS-specific lesion load and the pres-
ence of MS-specific gadolinium-enhancing lesions),
time to progression, overall survival, causes of death,
response to any MS-specific treatment required
posttransplantation, and incidence of transplantation-
related late effects and secondary malignancies.
Feasibility issues for this typeof long-term follow-up
study ofHSCT forMS include lack of comparable qual-
ity baseline data for the variety of patients and regimens
that contribute to the CIBMTR and EBMT databases
and differences inMS eligibility criteria for studies con-
ducted a decade ago compared with today. To obtain
a history of the course of disease retrospectively, the par-
ticipation of a study neurologist will be needed. Unam-
biguous milestones will need to be specified. Inclusion
of only subjects who were enrolled in any clinical trial
(not necessarily a transplantation study) and from a cen-
ter committed to clinical trials investigation might be
preferable, because such individuals will be more likely
to have sufficient documentation of their MS disease
course.MRIfindings consistentwithMSactivity include
new gadolinium-enhancing and, or new T2 lesions.
Comparison of imaging findings might be difficult,
because of either outdated techniques or the absence of
such evaluations. Quantitative assessment of lesion
load might not be possible in this type of study. The
newly harmonized MS disease-specific research forms
1080 Biol Blood Marrow Transplant 16:1076-1083, 2010M. C. Pasquini et al.will be used to collect posttransplantation information
for this long-term follow-up study, which will be a col-
laborative project of theCIBMTRandEBMT. For sites
reporting to CIBMTR, limited reimbursement is avail-
able for completion of the MS-specific research forms.
Allogeneic HSCT in MS: Long-Term Follow-Up
To investigate the potential of allogeneicHSCT to
stabilize or cure MS, we performed a cross-sectional
and retrospective clinical study to assess outcomes in
11 patients with coexistent MS who underwent alloge-
neic HSCT for hematologic malignancy. The experi-
ence of allogeneic HSCT for autoimmune diseases is
limited because this approach may be considered only
for those with very advanced nonmalignant diseases,
because of the generally unfavorable risk-benefit ratio
[15]. There are currently no clinical trials of allogeneic
HSCT as therapy for MS; however, for patients with
coincident autoimmunediseasewhounderwent alloge-
neic HSCT for treatment of malignancy, investigation
of MS-related outcomes provides an opportunity to
examine how transplantation affects the patient’s auto-
immune disease, as well as the effects of the underlying
immune dysregulation on transplantation outcome
[16]. Subjects were identified through research of the
CIBMTRdatabase or personal contact with transplan-
tation physicians worldwide. Ten patients alive at the
time of initiation of this study, and pathological sam-
ples from one patient who died after allogeneic
HSCT were evaluated. Study participants received
comprehensive follow-up, including clinical, neuro-
logic, and MRI evaluations, after providing informed
consent. Publication is pending (Richard A. Nash, per-
sonal communication). In addition, Lu et al. [17] re-
ported on a single patient with mild MS who received
a myeloablative preparative regimen and allogeneic
HSCT from a HLA- matched unrelated donor for
chronicmyelogenous leukemia. The patient developed
graft-versus-host disease and worsening (but not new)
neurologic symptoms. At 140 days post-HSCT, after
the patient died because of adenovirus hepatitis, post-
mortem central nervous system examination revealed
ongoing active and chronic active MS lesions. Most
hematolymphatic cells in the brain were recipient cells,
even though only donor cells were detected in the
peripheral blood. Further study of such cases is needed
to fully evaluate the potential of allogeneic HSCT to
affect the clinical course, and toxicities particular to
this therapy, for patients with MS.CLINICALTRIALS IN AUTOLOGOUS HSCT
FOR MS: CHALLENGES IN STUDY DESIGN
During the next few years, as the phase II clinical
trials of HSCT for MS currently underway come to
completion, it will be important to plan ahead for thenext studies, with special emphasis on randomized
phase III trials. This will be especially critical in the
event that international multicenter collaboration is
desired. Major issues in study design and implementa-
tion include feasibility, need for multidisuplinary study
teams, and the large sample sizes and years of observa-
tion required for outcomes assessment.
Feasibility
Patient accrual has been a challenge for clinical tri-
als of autologous HSCT for MS. The most significant
impediments to accrual include lack of wide accep-
tance by the neurology community because of the in-
vestigational status of the therapy, an insufficient
number of transplantation teams that include strong
functional partnerships between transplantation and
disease specialists, absence of training programs in
the field of HSCT for autoimmune diseases, narrow
eligibility criteria, referral patterns to transplantation
centers, and difficulty obtaining third-party payer ap-
proval to cover the costs of HSCT in the United States
and some European countries. The neurology com-
munity has been cautious to consider autologous
HSCT for MS because of concerns about safety, in-
cluding toxicities and the risk of mortality in a disorder
that, at least in the short-term, is not life-threatening.
The relatively high toxicity of HSCT versus existing
and experimental new therapies has been a major dis-
incentive for many neurologists to refer MS patients
to transplantation studies in the absence of convincing
evidence of efficacy. Furthermore, there is little enthu-
siasm to refer patients for additional phase II studies,
given the general acceptance that a phase III random-
ized clinical trial is what is needed to evaluate efficacy.
Given the concerns about the risk-benefit ratio of the
procedure, entry criteria for early studies were highly
selective for poor-prognosis patients with aggressive
MS that was too advanced, although as outcomes
have improved, it has become feasible to consider
more broad entry criteria. As is entirely appropriate
for a disease with a natural history that may be devas-
tating in the long term and has no known cure, other
potential novel therapies and competing drugs for
MS are continually being developed; studies of this
type may attract patients otherwise eligible for
HSCT. Sullivan et al. [18] have described the recent
challenges of obtaining insurance coverage in the
United States for a National Institutes of Health–
sponsored clinical trial of autologous HSCT for auto-
immune disease. Finally, patients may be reluctant to
enroll in randomized studies because of individual
treatment preferences of one study arm over another.
Study Team
Amultidisciplinary teamwith expertise inneurology,
imaging, immunology, hematology, and transplantation
Figure 2. Time course of MS and pre- and post-HCT events for MS research forms. The MS Disease-Specific Baseline form is used to capture
information about MS disease activity before HCT. Diagnostic information, as well as assessment of MS activity including EDSS, clinical relapses, and
MRI findings during the 2 years before HCT, are of particular interest. The same form is used to record baseline assessments both before mobilization
and after collection of the graft for autologous HCT, and before administration of the preparative regimen for allogeneic HCT. The MS Disease-Specific
Follow-Up Form is used to capture post-HCT information (see also Table 2).
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MS. Close partnership that includes real-time consul-
tation of neurology and HSCT physicians is required
both during and in follow-up of the transplantation
procedure, to provide the best patient care and appro-
priately evaluate disease response.Outcomes Assessment
The 30- to 40-year time course of MS evolution
[19], along with the heterogeneous nature of the
disease, necessitate several years of clinical follow-up
and relatively large sample sizes to ensure meaningful
assessment of clinical trial endpoints. Clinical assess-
ments include comparison of cumulative functional
disability measured using the EDSS [10] and, or num-
ber of clinical relapses and, or time to clinical relapse in
one treatment arm relative to the other. Success is then
defined as less progression of EDSS and, or fewer
relapses and, or a longer time to relapse and, or
progression. The requirement or not for further im-
munomodulatory therapy might serve as an adjunct
outcome. In contrast, to allow the opportunity for
smaller sample sizes and shorter follow-ups, recent
clinical studies evaluating alternative drug therapies
for MS have frequently used improvement of clinical
status after treatment in one arm relative to the other
arm as an outcome [20]. Whether early improvements
in disabilities indeed translate into longer progression-
free survival or other improvements in later MS
outcomes after HSCT is unclear, however. Additional
clinical assessments (eg, theMS Functional Composite
[MSFC]) have been incorporated in recent clinical
trials [21-24]; the MS Impact Scale (MSIS-29) [25] is
commonly used to assess quality of life. Investigations
of MRI surrogate markers [26-29] and biomarkers [30]
of MS are ongoing.CLINICALTRIALS IN AUTOLOGOUS HSCT
FOR MS: FUTURE DIRECTIONS
A consideration of options for the next clinical
study or group of studies is now timely. A future com-
parative prospective randomized clinical trial of trans-
plantation versus nontransplantation treatment is
clearly needed. Important questions in study design
will include sample size, transplantation regimen, non-
transplantation therapy or therapies, MS target
population, and outcomes to be analyzed, including
long-term follow-up. Issues of feasibility in study
design because of the very large number of subjects re-
quired to demonstrate a significant difference between
2 treatment options and, or the several years of obser-
vation needed are likely to remain challenges for future
studies. Potential nontransplantation comparators
might include rituximab, alemtuzumab, daclizumab,
cladribine, fingolimod, cyclophosphamide, mitoxan-
trone [31-36], and other new therapies currently in
development. A composite primary endpoint that
includes MRI as well as clinical functional assessments
could be used for phase II efficacy studies. For phase
III or pivotal clinical trials of therapy for MS, the
primary endpoint is a clinical functional assessment of
disease, as required by the US Food and Drug
Administration [37], with the EDSS most often used
for this purpose.
To continue the discussion of both study design
and operational challenges for a prospective random-
ized study of autologous HSCT for MS, representa-
tives of this workshop met again recently as part of
a larger ongoing international effort, which was re-
ported separately [38]. International collaboration,
including partnership with the CIBMTR and
EBMT, may be desirable and in fact may be critical
for successful completion of a definitive comparative
study. The use of a single protocol required at all
1082 Biol Blood Marrow Transplant 16:1076-1083, 2010M. C. Pasquini et al.sites versus comparable protocols in North America
and Europe will be an important consideration. The
use of a single protocol would ensure uniformity of
subject entry/exclusion criteria and study design. If
there are multiple protocols, comparable baseline as
well as follow-up assessments will be needed for all
subjects. A decentralized plan would offer individual
sites some degree of flexibility in site-specific proto-
col design and implementation and assume distrib-
uted responsibility for study costs. The regulatory
challenges particular to each country will need to
be addressed. Consideration of options for funding
from multiple sources, such as the US National
Institutes of Health, the national Multiple Sclerosis
Societies, and other national and international
resources, will be needed.ACKNOWLEDGMENTS
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